BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27051773)

  • 1. Successful treatment of livedoid vasculopathy with rivaroxaban.
    Evans JM; Jensen JD; Sami N
    JAAD Case Rep; 2015 Nov; 1(6):340-1. PubMed ID: 27051773
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
    Ramphall S; Rijal S; Prakash V; Ekladios H; Mulayamkuzhiyil Saju J; Mandal N; Kham NI; Shahid R; Naik SS; Venugopal S
    Cureus; 2022 Aug; 14(8):e28485. PubMed ID: 36051980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
    Seguí M; Llamas-Velasco M
    Front Med (Lausanne); 2022; 9():993515. PubMed ID: 36569162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrophie blanche: is it associated with venous disease or livedoid vasculopathy?
    Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
    Adv Skin Wound Care; 2014 Nov; 27(11):518-24; quiz 525-6. PubMed ID: 25325229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.
    Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
    J Am Acad Dermatol; 2013 Dec; 69(6):1033-1042.e1. PubMed ID: 24028907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche.
    Mimouni D; Ng PP; Rencic A; Nikolskaia OV; Bernstein BD; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):789-94. PubMed ID: 12752140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penile Livedoid Vasculopathy: First Reported Case.
    Hallak A; Bennett W; Tanbir MA; Donthamsetty SR; Vincent B
    Case Rep Vasc Med; 2023; 2023():6920383. PubMed ID: 37440957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab in the Treatment of Recalcitrant Livedoid Vasculopathy.
    Bhatt DM; Bhamburkar S; Madke B; Jangid SD; Khan A
    Cureus; 2023 Dec; 15(12):e50053. PubMed ID: 38186477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unilateral livedoid vasculopathy associated with involutional phase of cutaneous infantile hemangioma: the connection to coagulation disorders.
    Criado PR; Alavi A; Halpern I; Sotto MN; Kirsner RS
    Int J Low Extrem Wounds; 2013 Dec; 12(4):306-9. PubMed ID: 24043683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.
    Kerk N; Goerge T
    J Dtsch Dermatol Ges; 2013 May; 11(5):407-10. PubMed ID: 23437985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.
    Drabik A; Hillgruber C; Goerge T
    JMIR Res Protoc; 2014 Dec; 3(4):e73. PubMed ID: 25500152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Livedoid vasculopathy - A diagnostic and therapeutic challenge.
    Burg MR; Mitschang C; Goerge T; Schneider SW
    Front Med (Lausanne); 2022; 9():1012178. PubMed ID: 36262273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, Laboratory, Histopathological and Therapeutic Profile of Livedoid Vasculopathy: A Case Series of 17 Patients.
    Shah SR; Vyas HR; Doshi YJ; Shah BJ
    Indian Dermatol Online J; 2022; 13(6):771-774. PubMed ID: 36386750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
    Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
    Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.
    Gao Y; Jin H
    J Dermatolog Treat; 2022 Feb; 33(1):178-183. PubMed ID: 32116074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
    Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
    Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulcerative livedoid vasculopathy responding to clopidogrel.
    Kunzler E; Chong BF
    JAAD Case Rep; 2018 Mar; 4(2):203-205. PubMed ID: 29892667
    [No Abstract]   [Full Text] [Related]  

  • 18. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?
    Ishibashi M; Miyamoto J; Nagasaka T; Chen KR
    Am J Dermatopathol; 2009 May; 31(3):293-6. PubMed ID: 19384073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Livedoid vasculopathy as a coagulation disorder.
    Criado PR; Rivitti EA; Sotto MN; de Carvalho JF
    Autoimmun Rev; 2011 Apr; 10(6):353-60. PubMed ID: 21184847
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.